Renovorx (RNXT) closed at $1.04 on November 13, 2026, down 10.3% from the previous close, on volume of 814,439 shares (30-day average 438,630).
Data as of November 13, 2026.
RenovoRx Earnings Call Highlights Record Growth
TipRanks (Sat, 14-Nov 9:08 PM ET)
RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million
Globe Newswire (Thu, 5-Nov 4:05 PM ET)
Globe Newswire (Wed, 28-Oct 8:30 AM ET)
RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
Globe Newswire (Thu, 22-Oct 8:45 AM ET)
Globe Newswire (Wed, 7-Oct 8:30 AM ET)
Globe Newswire (Thu, 1-Oct 8:30 AM ET)
RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th
Globe Newswire (Wed, 2-Sep 8:30 AM ET)
Globe Newswire (Tue, 25-Aug 8:30 AM ET)
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
Globe Newswire (Fri, 21-Aug 8:30 AM ET)
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Renovorx trades on the NASDAQ stock market under the symbol RNXT.
As of November 16, 2026, RNXT stock price declined to $0.98 with 552,755 million shares trading.
RNXT has a beta of 1.20, meaning it tends to be more sensitive to market movements. RNXT has a correlation of 0.03 to the broad based SPY ETF.
RNXT has a market cap of $44.20 million. This is considered a Sub-Micro Cap stock.
Last quarter Renovorx reported $1 million in Revenue and -$.07 earnings per share. This beat revenue expectation by $4,400 and missed earnings estimates by -$.02.
In the last 3 years, RNXT traded as high as $2.59 and as low as $.53.
The top ETF exchange traded funds that RNXT belongs to (by Net Assets): VTI, VXF.
RNXT has underperformed the market in the last year with a price return of +0.6% while the SPY ETF gained +11.4%. RNXT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -22.2% and -26.3%, respectively, while the SPY returned -4.5% and -2.0%, respectively.
RNXT support price is $.97 and resistance is $1.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RNXT shares will trade within this expected range on the day.